Hubbry Logo
DronabinolDronabinolMain
Open search
Dronabinol
Community hub
Dronabinol
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Dronabinol
Dronabinol
Dronabinol
View on Wikipedia
from Wikipedia

Dronabinol
Clinical data
Trade namesMarinol, Syndros
Other names(−)-trans-Δ9-tetrahydrocannabinol
License data
Dependence
liability		Physical: Low
Psychological: Low–moderate
Addiction
liability		Relatively low[citation needed]
Routes of
administration		By mouth
Drug classCannabinoid
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityPOTooltip Oral administration: 6–20%
Onset of actionPO: 0.5–1 hour
Elimination half-life25–36 hours
Duration of actionPO: 4–6 hours
Identifiers
  • (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC21H30O2
Molar mass314.469 g·mol−1
3D model (JSmol)
Specific rotation−152° (ethanol)
Boiling point155–157 °C (311–315 °F) 0.05mmHg,[1] 157–160°C @ 0.05mmHg[2]
Solubility in water0.0028 mg/mL (23 °C)[3]
  • CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C)(C)C)O
  • InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1 checkY
  • Key:CYQFCXCEBYINGO-IAGOWNOFSA-N checkY
Part of a series on
Cannabis
Cannabis
Chemistry
  • Semi-synthetic cannabinoids
Pharmacology
Consumption
Economics
Effects
Forms
Law
Variants
  • Genus
  • Species
Related

Dronabinol (INNTooltip International Nonproprietary Name), sold under the brand names Marinol and Syndros, is the generic name for the molecule of (−)-trans-Δ9-tetrahydrocannabinol (THC) in the pharmaceutical context. It has indications as an appetite stimulant, antiemetic, and sleep apnea reliever[4] and is approved by the US Food and Drug Administration (FDA) as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting.[5][6][7]

Dronabinol is the principal psychoactive constituent enantiomer form, (−)-trans-Δ9-tetrahydrocannabinol, found in Cannabis sativa L. plants,[8] but can also be synthesized in laboratory. Dronabinol does not include any other tetrahydrocannabinol (THC) isomers or any cannabidiol (CBD).

Medical uses

[edit]

Low appetite and nausea

[edit]

Dronabinol is used to stimulate appetite and therefore weight gain in patients with HIV/AIDS and cancer. It is also used to treat chemotherapy-induced nausea and vomiting.[9][10]

Pain

[edit]

Dronabinol demonstrated analgesic efficacy in a majority of studies in chronic pain, the data in acute pain is less conclusive.[11]

Cannabis use disorder

[edit]

Dronabinol may be useful in treating cannabis addiction as it has been shown to reduce cannabis withdrawal symptoms and the subjective effects of cannabis.[12]

Sleep apnea

[edit]

Dronabinol demonstrates significant improvement in sleep apnea scores.[4][13][14][15] Phase 2B clinical trials were completed in 2017 for FDA approval for this indication.[16][17][18]

Adverse effects

[edit]

Common side effects of dronabinol include euphoria, drowsiness, dizziness, decreased motor coordination, anxiety, paranoia, confusion, and a rapid heartbeat, among others.[19]

Overdose

[edit]

In a mild overdose of dronabinol, the typical side effects are exacerbated, whereas a severe overdose presents with lethargy, slurred speech, severe ataxia, and orthostatic hypotension.[5][20]

Pharmacology

[edit]
Main article: Tetrahydrocannabinol § Pharmacology

History

[edit]

While dronabinol was initially approved by the United States Food and Drug Administration (FDA) on May 31, 1985,[21] it was not until May 13, 1986, the Drug Enforcement Administration (DEA), issued a Final Rule and Statement of Policy authorizing the "rescheduling of synthetic dronabinol in sesame oil and encapsulated in soft gelatin capsules from Schedule I to Schedule II" (DEA 51 FR 17476-78). This permitted medical use of Marinol, albeit with the severe restrictions associated with Schedule II status.[22] For instance, refills of Marinol prescriptions were not permitted.

On April 29, 1991, the Commission on Narcotic Drugs, in accordance with article 2, paragraphs 5 and 6, of the Convention on Psychotropic Substances of 1971, decided that Δ9-tetrahydrocannabinol (also referred to as Δ9-THC) and its stereochemical variants should be transferred from Schedule I to Schedule II of that Convention. This released Δ9-THC from many of the restrictions imposed by the convention, facilitating its marketing as medication.[23]

An article published in the April–June 1998 issue of the Journal of Psychoactive Drugs found that "Healthcare professionals have detected no indication of script-chasing or doctor-shopping among the patients for whom they have prescribed dronabinol". The authors state that Marinol has a low potential for abuse.[24][better source needed]

In 1999, in the United States, Marinol was rescheduled from Schedule II to Schedule III of the Controlled Substances Act, reflecting a finding that dronabinol had a potential for abuse less than that of cocaine and heroin.[21] This rescheduling constituted part of the argument for a 2002 petition for removal of cannabis from Schedule I of the Controlled Substances Act, in which petitioner Jon Gettman noted, "Cannabis is a natural source of dronabinol (THC), the ingredient of Marinol, a Schedule III drug. There are no grounds to schedule cannabis in a more restrictive schedule than Marinol".[25][better source needed]

In 2003, the World Health Organization Expert Committee on Drug Dependence recommended transferring THC to Schedule IV of the convention, citing its medical uses and low abuse potential.[26] In 2019, the Committee recommended transferring Δ9-THC to Schedule I of the Single Convention on Narcotic Drugs of 1961, but its recommendations were rejected by the United Nations Commission on Narcotic Drugs.[27]

Society and culture

[edit]

Brand names

[edit]

Dronabinol is marketed as Marinol and Syndros,[28] a registered trademark of Solvay Pharmaceuticals. Dronabinol is also marketed, sold, and distributed by PAR Pharmaceutical Companies under the terms of a license and distribution agreement with SVC pharma LP, an affiliate of Rhodes Technologies for Marinol and Insys Pharmaceuticals for Syndros.[citation needed] Dronabinol is available as a prescription drug (under Marinol and Syndros [29]) in several countries including the United States, Germany, South Africa and Australia.[30] In Canada, Tetra Bio-Pharma filed a New Drug Submission (NDS) with Health Canada for its Dronabinol Soft Gel capsules to be marketed as REDUVO™.[31] Tetra has two other dronabinol drugs with new routes of administration which limit first-pass metabolism; an inhaled THC-based dronabinol drug and their mucoadhesive-delivery dronabinol drug Adversa®, which are both in the accelerated 505(b)(2) New Drug Application (NDA) pathway for the U.S. and Canadian markets.[32]

In the United States, Marinol is a Schedule III drug, available by prescription, considered to be non-narcotic and to have a low risk of physical or mental dependence. Efforts to get cannabis rescheduled as analogous to Marinol have not succeeded thus far, though a 2002 petition has been accepted by the DEA. As a result of the rescheduling of Marinol from Schedule II to Schedule III, refills are now permitted for this substance. Marinol's U.S. Food and Drug Administration (FDA) approval for medical use has raised much controversy[33] as to why cannabis is still illegal at the federal level.[34]

Comparisons with medical cannabis

[edit]
Further information: Medical cannabis

Female cannabis plants not only contain dronabinol but at least 113 other cannabinoids,[35] including cannabidiol (CBD), thought to be the major anticonvulsant that helps people with multiple sclerosis;[36] and cannabichromene (CBC), an anti-inflammatory which may contribute to the pain-killing effect of cannabis.[37]

It takes over one hour for Marinol to reach full systemic effect,[38] compared to seconds or minutes for smoked or vaporized cannabis.[39] Mark Kleiman, director of the Drug Policy Analysis Program at UCLA's School of Public Affairs said of Marinol, "it wasn't any fun and made the user feel bad, so it could be approved without any fear that it would penetrate the recreational market, and then used as a club with which to beat back the advocates of whole cannabis as a medicine."[40]

Clinical trials comparing the use of cannabis extracts with Marinol in the treatment of cancer cachexia have demonstrated equal efficacy and well-being among subjects in the two treatment arms.[41] United States federal law currently registers dronabinol as a Schedule III controlled substance, but all other cannabinoids remain Schedule I, except various synthetic cannabinoids like nabilone and HU-308.[42][43]

The FDA has recognized that there can be cannabinoid impurities in pharmaceutical dronabinol including cannabinol, Δ8-Tetrahydrocannabinol, isotetrahydrocannabinol and Δ11-tetrahydrocannabinol.[44][45]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Dronabinol

View on Grokipedia
from Grokipedia
Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive constituent of , formulated for oral administration as an and . Approved by the U.S. (FDA) in 1985, it is indicated for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who fail to respond adequately to conventional therapy, and for anorexia with in patients with acquired immune deficiency syndrome (AIDS). As a partial agonist at cannabinoid receptors CB1 and CB2 primarily in the , dronabinol exerts its therapeutic effects through modulation of neurotransmitter release, contributing to suppression of emesis and enhancement of appetite, though it also produces dose-related psychoactive effects such as and altered that necessitate careful patient monitoring. Available in capsule form under the brand name Marinol and as a liquid solution under Syndros, dronabinol is classified as a III controlled substance under the U.S. , reflecting its accepted medical use alongside a moderate potential for physical and . Clinical trials supporting its approval demonstrated significant reductions in chemotherapy-induced and improvements in appetite and body weight in targeted populations, though efficacy varies with dosage and individual response, and adverse effects including dizziness, somnolence, and abdominal pain are common. Off-label investigations have explored its utility in conditions like and , yielding mixed results that do not yet warrant expanded indications. As the first FDA-approved oral medication, dronabinol represents a pharmacologically isolated alternative to smoked or ingested , bypassing variable plant-derived compositions while inheriting THC's complex interactions.

Chemical Structure and Pharmacology

Molecular Composition

Dronabinol, chemically designated as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, possesses the C21H30O2 and a molecular weight of 314.45 g/mol. This structure corresponds to the (-)-trans-Δ9- , featuring a dibenzopyran with a at position 3 and dimethyl groups at position 6. The specific at the 6a and 10a positions (6aR,10aR) is essential for its , as the enantiomeric (+)-trans form exhibits negligible affinity for receptors and lacks psychoactive effects. Unlike Δ9-THC extracted from Cannabis sativa, which varies in isomeric purity and accompanies other cannabinoids like CBD or CBN, dronabinol is manufactured through stereoselective total synthesis, such as acid-catalyzed cyclization of cannabidiol or coupling of olivetol with cyclic precursors. This synthetic route ensures >98% purity of the active (-)-trans isomer, free from plant-derived contaminants including pesticides, heavy metals, and microbial residues that can affect natural extracts. The absence of racemic mixtures or diastereomers in pharmaceutical-grade dronabinol distinguishes it from non-stereospecific syntheses, which yield inactive or partially active products.

Mechanism of Action

Dronabinol, the synthetic (–)-trans-Δ9-tetrahydrocannabinol, acts primarily as a at type 1 (CB1), which is coupled to Gi/o proteins and densely expressed in the , including areas regulating emesis and appetite such as the and . Activation of CB1 inhibits adenylate cyclase, decreasing intracellular cyclic AMP levels, and modulates voltage-gated calcium channels while enhancing activity, leading to presynaptic inhibition of neurotransmitter release, notably GABA and glutamate in relevant neural circuits. This receptor-mediated suppression underlies the compound's action by attenuating excitatory inputs to the center and orexigenic effects by disinhibiting hypothalamic feeding pathways. It exhibits weaker partial agonism at CB2 receptors, primarily on peripheral immune cells, though this contributes less to its core therapeutic profile. Preclinical radioligand binding assays demonstrate high CB1 affinity (Ki ≈ 35–41 nM) with selectivity over other receptors, supporting targeted signaling without broad off-target monoamine modulation seen in some psychotropics. In and models, dose-response curves for antiemetic efficacy plateau at moderate doses (e.g., 0.1–1 mg/kg), reflecting partial agonism's intrinsic efficacy ceiling, which caps maximal response and differentiates it from full agonists prone to receptor desensitization. Higher doses shift toward dysphoric or cataleptic effects via potential CB1 overactivation or secondary pathways, as evidenced by inverted U-shaped behavioral responses in locomotor assays. Lacking co-occurring phytocannabinoids such as (CBD), which antagonizes CB1 in plant extracts and mitigates THC-induced anxiety in preclinical paradigms, dronabinol's isolated action avoids entourage modulation, yielding more consistent but potentially narrower therapeutic windows without synergistic attenuation of adverse effects.

Pharmacokinetics and Metabolism

Dronabinol, administered orally as capsules or solution, exhibits near-complete gastrointestinal absorption of 90-95% following a single dose. However, extensive first-pass hepatic metabolism combined with its high lipid solubility results in low systemic bioavailability of only 10-20%. Interpatient variability in absorption and bioavailability is substantial, influenced by factors such as gastric emptying and genetic polymorphisms in metabolizing enzymes. Ingestion with food markedly enhances dronabinol's by delaying gastric emptying, which increases total exposure (AUC) approximately 2.5- to 2.9-fold while postponing the time to maximum plasma concentration (Tmax) by 4-5 hours; peak concentration (Cmax) remains relatively unchanged. Due to its , dronabinol distributes extensively into tissues with an apparent of about 10 L/kg and is highly bound (>95%) to plasma proteins; its primary , 11-hydroxy-Δ9- (11-OH-THC), shows similar distribution properties. Metabolism occurs predominantly in the liver via enzymes, with as the primary isoform responsible for to 11-OH-THC, an equipotent that achieves plasma concentrations comparable to the parent and extends psychotropic effects. contributes secondarily, and polymorphisms in (e.g., poor metabolizer alleles) cause significant interindividual differences in metabolite formation and clearance. Elimination of dronabinol and its metabolites is primarily fecal via biliary excretion (50-65%), with a smaller fraction (15-25%) renally excreted as hydroxylated and carboxylated derivatives. The terminal plasma half-life of dronabinol averages 25-36 hours, prolonged further by metabolites accumulating in adipose tissue, which enables detection of urinary cannabinoids for several days post-dose and informs forensic drug testing windows.

Approved Medical Indications

Chemotherapy-Induced Nausea and Vomiting

Dronabinol is approved by the U.S. for the treatment of and vomiting associated with cancer in patients who do not respond adequately to conventional antiemetics, with initial approval granted in based on trials involving highly emetogenic regimens such as cisplatin-containing protocols. This indication targets adult patients receiving moderate- to high-emetogenic , where standard prophylaxis with antagonists, neurokinin-1 antagonists, and corticosteroids may fail, particularly in breakthrough scenarios. The action of dronabinol stems from its at CB1 receptors in the emetic circuitry, including the and dorsal vagal complex, which suppresses proemetic signals from , serotonin, and other neurotransmitters without relying on 5-HT3 pathways predominant in acute-phase . This CB1-mediated inhibition provides causal efficacy against delayed-phase and occurring more than 24 hours post-chemotherapy, a phase where 5-HT3 antagonists demonstrate limited control due to waning receptor blockade and involvement of alternative pathways like tachykinins. Meta-analyses of randomized controlled trials substantiate dronabinol's superiority over for preventing , with an of approximately 3.8 for complete response in emesis control, though evidence quality is rated low due to small sample sizes and heterogeneity in older studies. One analysis of ten trials reported an 8.2% absolute risk reduction specifically for delayed CINV with dronabinol versus , highlighting its adjunctive value when first-line agents underperform. Comparative trials show dronabinol's efficacy aligns with or exceeds that of for refractory cases, with benefits most pronounced in cisplatin-induced emesis unresponsive to initial therapy. Recommended dosing begins at 5 mg/m² orally 1 to 3 hours before , followed by repeat doses of 5 mg/m² every 2 to 4 hours for up to 4 to 6 total administrations daily, with a maximum of 15 mg/m² per dose adjusted for tolerance. Antiemetic response correlates directly with plasma delta-9-THC concentrations exceeding 5 ng/mL, where levels above 10 ng/mL associate with markedly lower incidence compared to subtherapeutic exposures below this threshold.

Anorexia and Weight Loss in AIDS Patients

Dronabinol received U.S. Food and Drug Administration approval in December 1992 for treating anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS), based on evidence from controlled trials demonstrating appetite stimulation and modest weight gain. In the pre-antiretroviral therapy era, when HIV/AIDS often led to profound cachexia, dronabinol addressed a critical need for interventions to counteract involuntary weight loss exceeding 10% of baseline body weight, which correlated with increased mortality risk. A pivotal multicenter, randomized, double-blind, -controlled trial published in 1995 enrolled 139 AIDS patients with significant anorexia and at least 2.3 kg of prior , administering dronabinol at an initial dose of 2.5 mg twice daily, titrated up to 20 mg daily as tolerated over six weeks. Participants receiving dronabinol reported significantly greater improvement (76% vs. 46% in ) and achieved a mean of 0.8 kg compared to 0.2 kg in the group, with trends toward enhanced caloric intake and subjective mood elevation, though objective measures of nutritional status showed limited changes. No impact on survival outcomes was observed in this or subsequent long-term extensions, where dronabinol maintained tolerability up to 12 months in late-stage patients but did not alter disease progression. Dronabinol stimulates primarily through of cannabinoid-1 (CB1) receptors in the , a key regulator of feeding behavior, thereby enhancing orexigenic signaling and reducing via downstream effects on neuropeptides like . This central mechanism contrasts with peripheral actions and explains rapid-onset effects, though clinical benefits often diminish after 2-4 weeks due to receptor downregulation and tolerance, necessitating dose adjustments or intermittent use. In contemporary practice, post-antiretroviral therapy advancements have reduced the prevalence of severe AIDS-related , positioning dronabinol as an adjunctive option for non-responders to first-line agents like acetate, which yields superior weight gains (e.g., 2-3 kg over similar periods) but carries higher risks of . Head-to-head comparisons in patients confirm dronabinol's role in appetite enhancement without additive weight benefits when combined with megestrol, underscoring its utility in cases refractory to progestins or where psychoactive side effects are manageable.

Investigational and Off-Label Uses

Dronabinol has been examined in randomized controlled trials for the treatment of neuropathic pain, yielding mixed outcomes. In a 16-week crossover study of patients with chronic neuropathic pain, dronabinol (titrated to 5–15 mg twice daily) produced a mean pain intensity reduction of 1.87 points on a 0–10 numeric rating scale compared to placebo (p=0.015), deemed clinically relevant by the authors, though psychoactive effects contributed to 22% dropout rates versus 6% for placebo. A separate randomized trial in multiple sclerosis patients with central neuropathic pain reported significant VAS reductions (mean difference -0.62 on 0–10 scale) with dronabinol 5 mg twice daily, but benefits were modest and accompanied by higher adverse event withdrawals. Meta-analyses of THC-based therapies, including dronabinol, indicate average pain score decreases of approximately 8–9 mm on a 100-mm VAS versus placebo, often below thresholds for substantial clinical meaningfulness (<20–30 mm), with tolerability limited by neuropsychiatric side effects. These findings have not supported FDA approval for pain indications, highlighting evidence gaps in long-term efficacy and risk-benefit profiles. For , dronabinol has shown utility in mitigating withdrawal symptoms but limited success in achieving . A double-blind, -controlled administering dronabinol up to 40 mg/day during a 12-week outpatient program reported significant reductions in withdrawal severity (e.g., Cannabis Withdrawal Scale scores) and improved retention rates (77% vs. 61% for ), yet no difference in endpoints at week 12. Laboratory studies corroborate symptom relief, with dronabinol decreasing , , and craving in dependent users during periods, but maintenance dosing failed to outperform taper strategies in promoting sustained cessation. High-dose regimens (e.g., 30–90 mg/day) further alleviated withdrawal but did not enhance quit rates beyond symptom , underscoring its role as a symptomatic adjunct rather than a curative agent. Exploratory applications include , where phase II trials have demonstrated modest reductions in apnea-hypopnea index (AHI). In a randomized, placebo-controlled study, dronabinol 10 mg at lowered mean AHI by 32% (from 16.1 to 10.9 events/hour, p<0.001) in moderate OSA patients, with improvements in daytime sleepiness, though effects were partially offset by increased wakefulness. A 2024 crossover trial combining dronabinol (2.5–10 mg) with further reduced AHI by up to 50% versus monotherapy, but sample sizes were small (n=12–20) and long-term data absent. For , early investigations noted transient intraocular pressure lowering with oral THC analogs, but dronabinol-specific trials are sparse and reveal tachyphylaxis within hours, precluding routine . Overall, placebo-subtracted benefits in these areas remain small (<20% improvement in primary metrics) and warrant larger RCTs to address evidentiary shortcomings.

Safety Profile and Risks

Common Adverse Effects

In clinical trials involving AIDS patients (n=157) and those undergoing (n=317), central nervous system effects occurred in approximately 33% of patients receiving dronabinol, with about 25% reporting such effects in the first two weeks of treatment and roughly 4% per week thereafter for the subsequent six weeks, indicating a pattern of initial higher incidence that diminishes over time due to tolerance development. Common adverse effects, typically mild to moderate and resolving upon discontinuation, include dizziness, somnolence, abnormal thinking, euphoria, and paranoid reactions, each reported at incidences of 3-10% across gastrointestinal and antiemetic studies. Gastrointestinal effects such as abdominal pain, nausea, and vomiting also occurred at similar rates of 3-10%. Euphoria, while contributing to the drug's appetite-stimulating benefits, can impair cognition and is more pronounced in cannabinoid-naive users, with rates of 24% in antiemetic trials and 8% in appetite stimulation studies. These effects are dose-related and more frequent with early morning dosing or in opioid-naive individuals lacking tolerance to cannabinoids. Elderly patients and those with psychiatric histories require closer monitoring, as per product labeling, due to heightened susceptibility to CNS disturbances.

Neuropsychiatric and Cardiovascular Risks

Dronabinol administration carries risks of acute neuropsychiatric reactions, including , hallucinations, depersonalization, mood alterations, and , with elevated incidence at higher doses or in vulnerable individuals. These effects stem from its agonism at cannabinoid receptors, mirroring observations in use where regular exposure predicts psychotic disorders, particularly in those with such as family , yielding odds ratios of approximately 2 to 4. FDA prescribing information advises avoidance in patients with or active disorders like , , or depression, as dronabinol may precipitate or worsen symptoms, necessitating close monitoring if use is unavoidable. Cognitive deficits represent another concern, with acute dronabinol exposure impairing , , and , effects persisting in chronic users based on performance decrements in controlled tasks. demonstrate CB1 receptor downregulation following repeated administration, correlating with enduring impairments in learning and independent of withdrawal. Cardiovascular risks include dose-dependent due to sympathomimetic activity and , potentially leading to syncope, with meta-analyses of trials confirming elevated odds compared to . effects vary, encompassing occasional or , contraindicating use in patients with cardiovascular instability. These reactions underscore the need for dosing initiation and gradual titration to mitigate hypotensive episodes.

Dependence, Abuse Potential, and Overdose

Dronabinol, as a synthetic form of delta-9-tetrahydrocannabinol (THC), carries a risk of dependence consistent with (CUD) under criteria, which requires at least two of eleven symptoms such as tolerance, withdrawal, or unsuccessful efforts to cut down use within a 12-month period. Among users of medicinal products, including dronabinol, the prevalence of meeting CUD criteria ranges from approximately 10.6% using modified scales to 25-29% in broader pooled estimates. Withdrawal symptoms upon discontinuation, including , , decreased , and anxiety, are reported in regular users and can precipitate relapse, with clinical trials of dronabinol for CUD treatment showing reductions in withdrawal severity compared to but limited impact on long-term abstinence rates, often exceeding 70% relapse within weeks. Abuse potential stems from dronabinol's psychoactive effects, including and altered perception, which mimic those of smoked and can reinforce misuse in individuals with substance use histories. Human abuse liability studies indicate subjective effects comparable to oral THC from , though peak reinforcement is lower than smoked forms; however, prescription tracking data for capsule formulations like Marinol show no significant diversion or patterns exceeding therapeutic doses (typically 2.5-20 mg/day). The oral solution Syndros, containing dronabinol in dehydrated alcohol, prompted rescheduling to Schedule II in 2017 due to heightened , as its form facilitates diversion for intravenous injection, potentially yielding rapid-onset effects akin to illicit cannabinoids, unlike the capsule's barriers to non-oral routes. Overdose from dronabinol is characterized by dose-dependent central nervous system depression rather than lethality, with no documented human fatalities attributable solely to the drug even at supratherapeutic doses. Acute symptoms include extreme drowsiness, ataxia, agitation, hallucinations, seizures, and hypotension, managed supportively with monitoring, activated charcoal if recent ingestion, and benzodiazepines for agitation or seizures; dialysis is ineffective due to high protein binding and lipid solubility. Animal studies establish a high therapeutic index, with oral LD50 exceeding 40 mg/kg in rodents (up to 9000 mg/kg in some species), far above clinical exposures where peak plasma THC levels remain below 10 ng/mL. Human extrapolations suggest a median lethal dose around 30 mg/kg intravenously but substantially higher orally due to first-pass metabolism, underscoring minimal acute toxicity risk in therapeutic contexts.

Historical Development

Early Research and Synthesis

In 1964, and Yechiel Gaoni at the isolated pure Δ⁹-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive constituent of , from extracts. Their work involved chromatographic separation and structural elucidation via spectroscopic methods, marking the first identification of Δ⁹-THC in isolated form. This breakthrough enabled partial synthesis of Δ⁹-THC and laid the groundwork for pharmacological investigations, as prior studies had been hampered by impure plant extracts containing variable profiles. Following isolation, early preclinical research in the late and examined Δ⁹-THC's effects using synthetic forms to ensure consistency. Studies in animal models, including rats, revealed that Δ⁹-THC stimulated by increasing food intake, an effect attributed to central nervous system modulation. Antiemetic properties were also observed; for instance, Δ⁹-THC reduced emesis in ferrets challenged with emetogenic stimuli like morphine-6-glucuronide, demonstrating dose-dependent inhibition of retching and episodes. These findings highlighted Δ⁹-THC's potential to counteract through cannabinoid receptor interactions, later confirmed to involve CB₁ receptor agonism, as antagonist blockade reversed the antiemetic action. The inherent variability in Δ⁹-THC content across natural strains—ranging from trace amounts to over 20% in high-potency varieties—posed challenges for reproducible dosing in research and potential therapeutic applications. This spurred development of fully synthetic routes to Δ⁹-THC, with key advancements in the 1960s including via coupling of derivatives with precursors under acidic conditions. By the 1970s, optimized syntheses produced pharmaceutical-grade Δ⁹-THC (dronabinol), free from plant impurities and standardized for potency, facilitating controlled preclinical testing of analogs in and models.

FDA Approvals and Regulatory Milestones

Dronabinol, marketed as Marinol capsules, received initial FDA approval on May 31, 1985, for treating and associated with cancer in patients unresponsive to conventional . This decision relied on from controlled clinical trials, including multicenter randomized studies that established its antiemetic efficacy through reductions in vomiting episodes relative to or active comparators. The FDA expanded dronabinol's indications on December 22, 1992, to include anorexia associated with in AIDS patients, supported by randomized trials demonstrating stimulation and positive weight endpoints, such as mean gains of approximately 0.1 kg in dronabinol-treated groups versus losses in controls among evaluable participants. In July 2016, the FDA approved Syndros, a liquid oral solution formulation of dronabinol, for the same nausea/vomiting and anorexia indications, leveraging prior efficacy data from Marinol while addressing differences. On , 2017, the DEA reclassified FDA-approved dronabinol oral solutions to Schedule II under the via an interim final rule, reflecting abuse potential concerns distinct from the Schedule III status of capsule formulations; this followed post-approval labeling updates emphasizing psychiatric adverse reaction risks, including hallucinations and at higher doses, informed by data. Generic dronabinol capsules entered the market following expiration, with approvals dating to and subsequent ANDAs incorporating 2017 label revisions for enhanced neuropsychiatric warnings based on cumulative reports. No additional FDA approvals or indication expansions for dronabinol have occurred through 2025, despite ongoing federal reviews of rescheduling—such as the 2024 HHS recommendation to shift marijuana to Schedule III—which underscore the preexisting differentiated regulatory pathway for FDA-approved synthetic delta-9-THC products like dronabinol.

Controlled Substance Classification

Dronabinol, the synthetic form of delta-9-tetrahydrocannabinol (THC), is classified as a III under the (CSA), a designation established by the (DEA) based on its FDA-approved medical applications for chemotherapy-induced and AIDS-related anorexia, coupled with evidence of moderate to low potential for abuse and relative to Schedules I and II. This placement contrasts with natural THC found in , which remains in Schedule I due to the lack of accepted medical use for the plant material and higher perceived abuse potential in uncontrolled forms; dronabinol's pharmaceutical purity and dosing enable accepted safety for medical use, satisfying CSA criteria under 21 U.S.C. § 812(b)(3) for substances with abuse liability less than Schedule II drugs like opioids, though psychoactive effects necessitate controls to mitigate risks. However, specific FDA-approved oral solutions of dronabinol, such as Syndros, are scheduled in II owing to formulation-specific factors influencing abuse potential assessments. The DEA's scheduling rationale emphasizes dronabinol's low profile—evidenced by clinical studies showing withdrawal symptoms milder than those of or —while acknowledging euphoric and perceptual effects that justify quotas on aggregate production (e.g., established annually under 21 CFR § 1308.11 to curb excess supply). Diversion monitoring by the DEA reveals minimal illicit trafficking of dronabinol compared to street , with pharmaceutical intercepts representing a negligible fraction of overall seizures, attributable to its controlled dispensing and less appealing street economics versus unregulated plant sources. Internationally, dronabinol aligns with Schedule II equivalents under the 1971 , following recommendations for delta-9-THC derivatives, though implementation varies; in the , it is regulated as a prescription-only without uniform scheduling, permitting medical access under national pharmaceutical laws rather than narcotic-level restrictions. This reflects criteria prioritizing therapeutic utility and limited risks from supervised use, distinct from broader controls.

Access, Prescribing, and Rescheduling Context

Dronabinol, marketed as Marinol or Syndros, is federally available by prescription as a Schedule III under the , allowing for refills and lower regulatory barriers compared to Schedule I or II substances. Prescribing patterns exhibit significant state-level variation, with higher utilization observed in regions lacking legal access to state-regulated products, such as southern states where programs are limited or absent, reflecting substitution dynamics amid federal-state policy conflicts.00655-9/fulltext) For instance, data from 2016–2020 revealed dronabinol prescriptions per enrollee ranging from 136.4 times higher in compared to , with 17 states reporting zero prescriptions, often correlating with differing state availability and reimbursement policies. Insurance coverage for dronabinol remains inconsistent across payers and states, with reimbursements declining 66.3% from 2016 to 2020 amid variable state formularies and requirements, while private insurers may deny claims for off-label uses lacking compendial support. The U.S. Department of Health and Human Services' 2024 rescheduling of marijuana from Schedule I to III, finalized by the DEA, imposes no direct changes to dronabinol's longstanding Schedule III status or prescribing protocols, as it pertains to FDA-approved synthetic THC formulations rather than crude plant material. This shift, however, alleviates Schedule I research restrictions, potentially easing studies on dronabinol-cannabis combinations, though FDA approval for expanded indications continues to demand phase III trials demonstrating safety and efficacy beyond existing nausea and stimulation uses. Off-label prescribing of dronabinol, such as for or neuropsychiatric conditions outside FDA labeling, heightens clinician liability exposure, particularly for adverse neuropsychiatric effects like , , or , which occur in ≥3% of users and may invite claims if or standard-of-care deviations are alleged. Courts have held physicians accountable for negligent off-label decisions, emphasizing documentation of risks and alternatives, though off-label status alone does not preclude successful defense if evidence supports the use. Federal payers like Medicare have denied coverage for such applications absent explicit compendia backing, amplifying access barriers and underscoring persistent regulatory scrutiny.

Societal and Clinical Context

Formulations and Brand Names

Dronabinol is commercially available in oral capsule and liquid solution formulations. The capsule form, originally marketed as Marinol, contains dronabinol in within soft gelatin capsules available in strengths of 2.5 mg, 5 mg, and 10 mg per capsule. Generic dronabinol capsules in these strengths have been available since patent exclusivity expired, providing equivalent therapeutic options. The liquid formulation, branded as Syndros, is an oral solution with a concentration of 5 mg dronabinol per mL, incorporating 50% dehydrated alcohol and as excipients to enhance and absorption. This alcohol-based vehicle addresses formulation challenges in achieving consistent delivery from solution compared to capsules, though the product requires and exhibits stability limitations, with a post-opening expiration of approximately 42 days. No generic equivalent for the Syndros solution has been approved as of 2025. Dosing schedules for these formulations differ by indication: for , administration occurs multiple times daily (up to four to six doses) starting 1-3 hours prior to treatment, while for appetite stimulation in AIDS-related anorexia, twice-daily (BID) dosing before meals is standard.

Economic Factors and Prescribing Patterns

The cost of dronabinol treatment reflects a substantial disparity between branded and generic formulations, with monthly expenses for branded capsules typically ranging from $200 to $500 depending on dosage and pricing, while generic equivalents can be obtained for $50 or less using discount programs. provides coverage for dronabinol in 100% of plans, but access is constrained by requirements for —particularly for off-label uses—quantity limits, and copays of $1 to $2 after the , contributing to overall economic barriers for elderly patients. Prescribing patterns indicate limited utilization, with dronabinol prescriptions decreasing by 25.3% across U.S. states from to amid rising availability of alternative cannabinoids like CBD. Geographic variances are pronounced, showing an inverse correlation with state-level access; states with established programs exhibit lower dronabinol prescription rates per capita, with some reporting near-zero prescriptions in populations during this period. This trend aligns with broader shifts toward non-pharmaceutical options in legalized jurisdictions, reducing demand for synthetic THC despite its FDA-approved indications. Key barriers to wider prescribing include mandatory prior authorizations for non-FDA-labeled uses, which delay access and increase administrative burden, as well as reluctance stemming from the drug's documented liability under its Schedule III classification. Physicians must assess patient risk for misuse prior to initiation, fostering hesitation even in eligible cases like chemotherapy-induced , where supports but regulatory scrutiny amplifies perceived risks.

Comparisons and Debates

Versus Natural Cannabis and Whole-Plant Extracts

Dronabinol provides a standardized, pharmaceutical-grade form of delta-9-tetrahydrocannabinol (THC) without the variability inherent in natural products, which can differ significantly in cannabinoid potency and composition across batches due to cultivation, harvesting, and processing factors. Unlike dispensary-sourced , dronabinol avoids plant-derived contaminants such as pesticides, (e.g., lead, , mercury), microbes, and residual solvents, which have been detected in unregulated or variably tested whole-plant extracts and pose risks of or . Synthetic production ensures consistent dosing per capsule or solution, mitigating uncertainties in THC content that affect natural reliability. In terms of psychoactive and therapeutic effects, dronabinol replicates the core euphoric and appetite-stimulating actions of THC found in natural but lacks (CBD) and other minor cannabinoids or present in whole-plant extracts, which may modulate THC's side effects. CBD has been shown to counteract THC-induced anxiety and in preclinical and human studies, potentially making pure THC formulations like dronabinol more prone to these adverse reactions at equivalent doses. Randomized controlled trials comparing oral dronabinol to inhaled or oral for chemotherapy-induced have found comparable antiemetic efficacy, though patients often report better subjective tolerance and preference for natural due to faster onset and entourage effects from multiple compounds. Regulatory distinctions further differentiate access: dronabinol's classification as a Schedule III under the federal facilitates prescribing and pharmacy dispensing with recognized medical value and lower abuse potential relative to pure THC isolates, avoiding the federal illegality of Schedule I despite state-level medical programs. This enables insurance coverage and standardized for dronabinol, contrasting with the legal conflicts, variable state enforcement, and lack of federal oversight for whole-plant distribution as of October 2025, even amid ongoing proposals to reschedule marijuana to Schedule III.

Empirical Efficacy Evidence and Criticisms

Meta-analyses of randomized controlled trials have demonstrated dronabinol's efficacy in reducing refractory to standard antiemetics, with cannabinoids including dronabinol yielding an of 3.82 for complete response compared to across multiple studies involving thousands of patients. Similar analyses confirm statistically significant improvements in emetic episodes, though effect sizes vary by emetogenicity, with relative risks for control often exceeding 2 in moderately emetogenic settings. For appetite stimulation in conditions like AIDS-related , trial data show modest weight gain and caloric intake increases, but these benefits diminish in broader applications beyond approved indications, where meta-analytic effect sizes are small or inconsistent. Criticisms of the evidence base highlight methodological limitations, including short trial durations—typically 4-8 weeks—that fail to account for tolerance development observed in longer-term studies, where escalating doses are needed to maintain effects on withdrawal or appetite. Clinical trials often exclude vulnerable populations such as those with psychiatric histories or substance use disorders, potentially inflating perceived safety by underrepresenting real-world risks like exacerbated or , which dronabinol can precipitate via CB1 receptor agonism in susceptible individuals. Publication bias is suspected in research, with analyses and Egger's tests indicating overrepresentation of positive outcomes, particularly in non-oncology uses, undermining claims of broad efficacy. Proponents emphasize dronabinol's role in providing accessible pharmacotherapy for underserved patients unresponsive to conventional treatments, citing its oral formulation as a practical alternative amid regulatory barriers to natural cannabis. Skeptics counter that its dependency profile—evidenced by withdrawal symptoms akin to opioids upon discontinuation—lacks commensurate analgesic potency, raising concerns over normalized psychiatric risks without proportional therapeutic gains, especially given academia's tendency to underemphasize adverse events in pro-cannabinoid narratives influenced by funding and ideological biases. Long-term data gaps further complicate causal attributions, as acute trial benefits may not translate to sustained outcomes under chronic dosing.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK557531/
  2. https://go.drugbank.com/drugs/DB00470
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf
  5. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=2424
  6. https://link.springer.com/article/10.1007/s13738-021-02212-0
  7. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000AdminCorres.pdf
  8. https://patents.google.com/patent/US7323576B2/en
  9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01259/full
  10. https://www.annualreviews.org/doi/pdf/10.1146/annurev.pharmtox.38.1.179
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5719102/
  12. https://www.scientificamerican.com/article/some-of-the-parts-is-marijuana-rsquo-s-ldquo-entourage-effect-rdquo-scientifically-valid/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10452568/
  14. https://www.ncbi.nlm.nih.gov/books/NBK564166/
  15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf
  16. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000ClinPharmR.pdf
  17. https://pubmed.ncbi.nlm.nih.gov/16237477/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4869612/
  19. https://jnccn.org/abstract/journals/jnccn/10/4/article-p487.xml
  20. https://www.dovepress.com/dronabinol-for-chemotherapy-induced-nausea-and-vomiting-unresponsive-t-peer-reviewed-fulltext-article-CMAR
  21. https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3883513/
  23. https://www.sciencedirect.com/science/article/pii/S2468294225000747
  24. https://cdn.mdedge.com/files/s3fs-public/issues/articles/CO_jan_20-26_navari.pdf
  25. https://jamanetwork.com/journals/jama/fullarticle/2338251
  26. https://www.oncologynurseadvisor.com/features/dronabinol-for-chemotherapy-induced-nausea-and-vomiting-unresponsive-to-antiemetics/2/
  27. https://link.springer.com/article/10.1007/s00280-017-3387-5
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5573753/
  29. https://www.drugs.com/pro/dronabinol.html
  30. https://www.researchgate.net/publication/303029353_Dronabinol_for_chemotherapy-induced_nausea_and_vomiting_unresponsive_to_antiemetics
  31. https://www.cannabisevidence.org/clinician-resources/clinician-briefs/cannabis-for-cinv/
  32. https://pubmed.ncbi.nlm.nih.gov/7730690/
  33. https://www.sciencedirect.com/science/article/pii/S0885392497000389
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11331011/
  35. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00293/full
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5879974/
  37. https://www.sciencedirect.com/science/article/pii/S0885392404000053
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC5804828/
  39. https://academic.oup.com/painmedicine/article/23/8/1409/6519324
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC8637910/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2733248/
  42. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.867878/full
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC5806568/
  44. https://academic.oup.com/sleep/article/48/4/zsae276/7908945
  45. https://www.researchgate.net/publication/338809798_The_Effect_of_Orally_Administered_Dronabinol_on_Optic_Nerve_Head_Blood_Flow_in_Healthy_Subjects-A_Randomized_Clinical_Trial
  46. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205525Orig1s009lbledt.pdf
  47. https://www.drugs.com/monograph/dronabinol.html
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC2424288/
  49. https://pubmed.ncbi.nlm.nih.gov/21321675/
  50. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.596601/full
  51. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf
  52. https://www.sciencedirect.com/science/article/abs/pii/S1544319121001114
  53. https://emedicine.medscape.com/article/286661-clinical
  54. https://journals.sagepub.com/doi/full/10.1177/0269881120986393
  55. https://www.sciencedirect.com/science/article/pii/S0376871624001844
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3154755/
  57. https://www.sciencedirect.com/science/article/abs/pii/S037687161200292X
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC4013220/
  59. https://pubmed.ncbi.nlm.nih.gov/9692381/
  60. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000SumR.pdf
  61. https://www.federalregister.gov/documents/2017/03/23/2017-05809/schedules-of-controlled-substances-placement-of-fda-approved-products-of-oral-solutions-containing
  62. https://www.ncbi.nlm.nih.gov/books/NBK563174/
  63. https://pubs.acs.org/doi/10.1021/ja01062a046
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC8746417/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC1760722/
  66. https://pubmed.ncbi.nlm.nih.gov/11606489/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7907797/
  68. https://www.ncbi.nlm.nih.gov/books/NBK230708/
  69. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=54890
  70. https://www.sciencedirect.com/science/article/pii/0885392494001174
  71. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf
  72. https://www.dea.gov/sites/default/files/2020-06/Marijuana-Cannabis-2020_0.pdf
  73. https://deadiversion.usdoj.gov/schedules/marijuana/Maintaining_Marijuana_in_Schedule_I_of_the_Controlled_Substances_Act.pdf
  74. https://www.dea.gov/sites/default/files/2024-05/2016-17954-HHS.pdf
  75. https://www.federalregister.gov/documents/2019/03/01/2019-03662/international-drug-scheduling-convention-on-psychotropic-substances-single-convention-on-narcotic
  76. https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_procedures_detailed.pdf
  77. https://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10315157/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC2719453/
  80. https://medicareadvocacy.org/lawsuit-settlement-allows-medicare-coverage-for-off-label-medication/
  81. https://www.drugs.com/availability/generic-marinol.html
  82. https://syndros.com/
  83. https://www.drugs.com/availability/generic-syndros.html
  84. https://reference.medscape.com/drug/marinol-syndros-dronabinol-342047
  85. https://www.goodrx.com/marinol
  86. https://www.drugs.com/price-guide/dronabinol
  87. https://www.goodrx.com/dronabinol/medicare-coverage
  88. https://www.healthline.com/health/medicare/does-medicare-cover-medical-marijuana
  89. https://karger.com/mca/article/6/1/58/852998/Pronounced-State-Level-Disparities-in-Prescription
  90. https://www.goodrx.com/dronabinol/marinol-vs-marijuana-whats-the-difference
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC6177718/
  92. https://encorelabs.com/common-contaminants-found-when-testing-cannabis/
  93. https://www.cerilliant.com/shoponline/OpenDocument.aspx?DocumentID=38
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC3691841/
  95. https://www.verywellhealth.com/treating-anxiety-with-cbd-vs-thc-what-to-know-8417226
  96. https://norml.org/marijuana/library/marinol-vs-natural-cannabis/
  97. https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
  98. https://www.findlaw.com/cannabis-law/cannabis-laws-and-regulations/what-s-the-difference-between-marinol-and-medical-marijuana.html
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC3325767/
  100. https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.21030320
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC8778752/
  102. https://www.cannabisevidence.org/wp-content/uploads/2023/12/Cannabis-for-CINV-Dec-2023.pdf
  103. https://www.nature.com/articles/s41386-022-01322-4
  104. https://www.bmj.com/content/382/bmj-2022-072348
  105. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02459-1
Add your contribution
Related Hubs
User Avatar
No comments yet.